Our current pipeline is represented in the diagram below.
The lead asset, CLK inhibitor CTX-712, is in US phase 1/2 clinical study (NCT05732103). Asset which is licensed out to Ono Pharmaceutical Company, MALT1 inhibitor CTX-177(ONO-7018) is in US Phase 1 clinical study.
※AML……Acute myeloid leukemia
※MDS……Myelodysplastic syndrome
※Chordia grants global rights of the CTX-177 to Ono Pharmaceuticals in Dec. 2020
